Cumberland Pharmaceuticals Inc.
NASDAQ:CPIXDrug Manufacturers - Specialty & Generic
-$0.06 today
- Market cap
- $98.52M
- Beta
- 0.10
- P/E (TTM)
- -11.5
- EPS (TTM)
- -$0.48
Volume 0.16M
Average 0.97M
CPIX Pre-Tax Margin
Income before tax as a percentage of revenue.
Cumberland Pharmaceuticals Inc.NASDAQ: CPIX
Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026
Pre-tax margin narrows to -34.4%
Pre-tax margin was -34.4% in Q1 FY2026, down 45.1 pp from a year earlier. On a trailing-twelve-month basis it was -17.2%, down 9.1 pp year over year. Over 3 fiscal years it widened by 6.9 pp.
Context
- Pre-tax margin widened in 1 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Pre-Tax Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -6.3%
- Year-over-year change
- +10.7pp
| Period | Period end | Pre-Tax Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -6.3% | +10.7pp |
| FY2024 | 2024-12-31 | -17.1% | -1.2pp |
| FY2023 | 2023-12-31 | -15.9% | -2.6pp |
| FY2022 | 2022-12-31 | -13.3% | +2.2pp |
| FY2021 | 2021-12-31 | -15.5% | — |
Pre-Tax Margin vs competitors
How CPIX compares with its peers on the latest reported figures
- CPIX's LTM Mar 2026 pre-tax margin of -17.2% is the highest of the 3 companies compared; the peer median is -295.3%.
- Its year-over-year change of -9.1 pp is the highest of 3, against a peer median of -154.8 pp.
- Over three fiscal years its change of +6.9 pp compares with a peer median of -344.9 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | -17.2% | -9.1 pp | +6.9 pp | |
| LTM Mar 2026 | -245.1% | -70.9 pp | -265.4 pp | |
| LTM Dec 2025 | -345.4% | -238.7 pp | -424.5 pp | |
| FY2025 | — | — | — | |
| Peer median (excluding CPIX) | -295.3% | -154.8 pp | -344.9 pp | |
Competitors are the stored peer set for CPIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 35.99M | 42.01M | 39.55M | 37.87M | 44.52M |
| Cost of Revenue | 8.81M | 9.12M | 6.07M | 6.59M | 6.67M |
| Gross Profit | 27.17M | 32.89M | 33.49M | 31.28M | 37.85M |
| Gross Margin | 75.5% | 78.3% | 84.7% | 82.6% | 85.0% |
| Research & Development | 5.68M | 6.69M | 5.83M | 4.82M | 5.57M |
| Selling, General & Admin | 24.8M | 26.84M | 29.1M | 28.15M | 31.05M |
| Operating Expenses | 34.85M | 38.6M | 43.04M | 37.71M | 40.65M |
| Depreciation & Amortization | 4.61M | 5.33M | 8.1M | 6.04M | 5.29M |
| EBITDA | (857.83K) | 332.92K | 2.49M | 182.42K | 2.96M |
| EBITDA Margin | -2.4% | 0.8% | 6.3% | 0.5% | 6.6% |
| Operating Income | (7.68M) | (5.7M) | (9.55M) | (6.43M) | (2.79M) |
| Operating Margin | -21.3% | -13.6% | -24.2% | -17.0% | -6.3% |
| Interest Income | 26.08K | 98.41K | 286.85K | 334.44K | 476.75K |
| Interest Expense | 98.03K | 586K | 667.86K | 605.51K | 495.99K |
| Other Income / Expenses | 2.12M | 123.74K | 3.27M | (33.98K) | (32.46K) |
| Income Before Tax | (5.56M) | (5.58M) | (6.28M) | (6.47M) | (2.82M) |
| Pre-Tax Margin | -15.5% | -13.3% | -15.9% | -17.1% | -6.3% |
| Income Tax Expense | 34.89K | 68.85K | 45.77K | (22.67K) | 40.26K |
| Net Income | (3.51M) | (5.57M) | (6.28M) | (6.48M) | (2.84M) |
| Net Margin | -9.7% | -13.3% | -15.9% | -17.1% | -6.4% |
| EPS (Basic) | (0.24) | (0.38) | (0.44) | (0.46) | (0.19) |
| EPS (Diluted) | (0.24) | (0.38) | (0.44) | (0.46) | (0.19) |
| Weighted Avg Shares | 14.9M | 14.56M | 14.3M | 14.06M | 14.96M |
| Weighted Avg Shares (Diluted) | 14.9M | 14.56M | 14.3M | 14.06M | 14.96M |
Cumberland Pharmaceuticals Inc.
NASDAQ:CPIX
Intrinsic Alpha fair value
Locked
Current Price
$6.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.